Dennis L. Kasper, M.D., is executive dean for academic programs, William Ellery Channing Professor of Medicine, and professor of microbiology and molecular genetics at Harvard Medical School. He also serves as director of the Channing Laboratory and as a senior physician at Brigham and Women’s Hospital. With his colleagues and students, Dr. Kasper studies the molecular basis of bacterial pathogenesis, applying the resulting knowledge to enhance understanding of the interactions of bacterial surface virulence factors with host defenses. Dr. Kasper’s studies focus on the molecular and chemical characterization of important bacterial virulence factors such as capsular polysaccharides, surface proteins, and toxins. The ultimate goal is to develop vaccines and immunomodulatory molecules to prevent bacterial infections and their complications. Dr. Kasper is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science as well as a member of the Institute of Medicine.
Don P. Metzgar, Ph.D., is a vaccine developer with a career spanning 34 years in research, manufacturing, development, and testing of vaccines. He has developed and licensed or supervised the development and licensing of 16 new or improved vaccines. Dr. Metzgar retired in 1994 from Connaught Laboratories, Ltd., as senior vice president with responsibilities for product development, including manufacturing, quality operations, medical affairs, regulatory affairs, engineering, and maintenance for the United States and Canada. He has served on the National Vaccine Advisory Committee. Dr. Metzgar maintains a relationship with his former employer as a consultant.
Hugh H. Tilson, M.D., Dr.P.H., is clinical professor of epidemiology and health policy and senior adviser to the dean at the University of North Carolina School of Public Health. Dr. Tilson is a practicing epidemiologist and outcomes researcher, with a career in preventive medicine and public health that spans more than 30 years and that includes service as a director of both state and local health departments and as vice president for worldwide epidemiology, surveillance, and policy research at GlaxoWellcome. He is the author of more than 100 papers in the fields of epidemiology, outcomes and policy research, and public health; he is a fellow of the American College of Epidemiology; and he is former vice-chair of the American Board of Preventive Medicine. Dr. Tilson also served as president of the American College of Preventive Medicine from 1995 to 1997 and was founding co-president of the International Society for Pharmacoepidemiology. He serves as an adviser and consultant in health outcomes, drug safety, and evidence-based health policy to regulatory and government agencies as well as pharmaceutical companies.